Analgesics and sedatives in critically ill newborns and infants: the impact on long-term neurodevelopment
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Treatment responses vary and depend on dosing, health profile, and monitoring
Because it has overlapping physiological roles in the body, a folate deficiency can have a very similar clinical picture to B12 deficiency
Additive and flavour free
Hexarelin is a synthetic analog of ghrelin and stimulates the release of growth hormone
